All In Biotech

Drug Trial Radar · NCT04180150

A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B

A Randomized, Double-blinded, Placebo-controlled, Phase IIa Study of TQ-A3334 Combined With Entecavir in the Treatment of Untreated or HBV DNA Negative Subjects With Chronic Hepatitis B

Last checked: Nov 19, 2026Latest source record: Dec 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

12

Planned (sponsor's estimate)

Start

Nov 18, 2019

Primary completion

Sep 30, 2020

Study completion Dec 31, 2021

Sponsor

Sponsor type
Industry
First posted
Nov 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blinded, placebo-controlled, phase IIa study to evaluate safety and efficacy of TQ-A3334 combined with entecavir in the untreated or HBV DNA negative subjects with Chronic Hepatitis B.

Conditions

  • Chronic Hepatitis B

Interventions

  • TQ-A3334Drug

    TQ-A3334 is a kind of TLR7 receptor agonist.

  • PlaceboDrug

    Placebo is a treatment which is designed to have no therapeutic value.

  • Entecavir TabletDrug

    Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.
  2. TmaxTime frame: Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.
  3. AUC0-tTime frame: Hour 0, 5, 10, 20, 30 minutes, 1, 2 , 3 , 6 , 12, 24, 72 , 168 hours post-dose at week 1 and week 12; Hour 0 of week 4, week 7, week 9, week 11.
  4. CytokineTime frame: Hour 0, 1.5 , 12 , 24 , 72 hours post-dose at week 1 and week 12; Hour 0 at week 7.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The second affiliated hospital of chongqing medical university

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • The first hospital of Jilin University

    Changchun, Jinlin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.